The role of endothelial insulin signaling in the regulation of glucose metabolism

Reviews in Endocrine and Metabolic Disorders

Volumn 14, Issue 2, 2013, Pages 207-216

  Kubota, Tetsuya ^a,b   Kubota, Naoto ^a,b,c   Kadowaki, Takashi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Capillary recruitment; Endothelial cell; Endothelial nitric oxide synthase; Insulin signaling; Insulin transport; Skeletal muscle insulin resistance

Indexed keywords

1 METHYLXANTHINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INSULIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N(G) METHYLARGININE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RAS PROTEIN; SOS PROTEIN;

ARTICLE; CONTRAST ENHANCED ULTRASOUND; CONTRAST ENHANCEMENT; ECHOGRAPHY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INTRACELLULAR TRANSPORT; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; INSULIN; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; NITRIC OXIDE SYNTHASE TYPE III;

EID: 84879690756     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-013-9242-z     Document Type: Article

References (88)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus present and future perspectives. Nat Rev Endocrinol. 2011;8:228-36.
2. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129-40.
3. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor: The DECODE Study. Diabetologia. 2004;47:2118-28.
4. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371:1800-9.
5. Hogan P, Dall T, Nikolov P. American diabetes association: economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-32.
6. DeFronzo R, Gunnarsson R, Ojorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149-55.
7. Turinsky J, O'Sullivan DM, Bayly BP. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem. 1990;265:16880-5.
8. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103:253-9.
9. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002;51:2005-11.
10. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011;121:1858-70.
11. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852-71.
12. Long YC, Zierath JR. Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am J Physiol Endocrinol Metab. 2008;295:E545-52.
13. Vincent MA, Clerk LH, Rattigan S, Clark MG, Barrett EJ. Active role for the vasculature in the delivery of insulin to skeletal muscle. Clin Exp Pharmacol Physiol. 2005;32:302-7.
14. Yang YJ, Hope ID, Ader M, Bergman RN. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest. 1989;84:1620-8.
15. Jansson PA, Fowelin JP, von Schenck HP, Smith UP, Lönnroth PN. Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Importance of the endothelial barrier for insulin. Diabetes. 1993;42:1469-73.
16. Miles PD, Levisetti M, Reichart D, Khoursheed M, Moossa AR, Olefsky JM. Kinetics of insulin action in vivo. Identification of rate limiting steps. Diabetes. 1995;44:947-53.
17. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806.
18. Nystrom FH, Quon MJ. Insulin signaling: metabolic pathways and mechanisms for specificity. Cell Signal. 1999;11:563-74.
19. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signaling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85-96.
20. Boller S, Joblin BA, Xu L, Item F, Trüb T, Boschetti N, et al. From signal transduction to signal interpretation: an alternative model for the molecular function of insulin receptor substrates. Arch Physiol Biochem. 2012;118(3):148-55.
21. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest. 1998;101:1784-8.
22. Kubota T, Kubota N, Moroi M, Terauchi Y, Kobayashi T, Kamata K, et al. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation. 2003;107:3073-80.
23. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-5.
24. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539-45.
25. 2+ but requires phosphorylation byAkt at Ser(1179). J Biol Chem. 2001;276:30392-8.
26. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physio. 2003;284:R1-12.
27. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007;3:46-56.
28. Potenza MA, Marasciulo FL, Chieppa DM, Brigiani GS, Formoso G, Quon MJ, et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol. 2005;289:H813-22.
29. Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab. 2009;297:E568-77.
30. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43:1066-84.
31. Ohkita M, Tawa M, Kitada K, Matsumura Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci. 2012;119(4):302-13.
32. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-904.
33. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001;22:36-52.
34. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med. 2007;262:173-83.
35. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006;55:691-8.
36. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, et al. Characterization of selective resistance to insulin signaling in the vasculature ofobese Zucker (fa/fa) rats. J Clin Invest. 1999;104:447-57.
37. Gogg S, Smith U, Jansson PA. Increased MAPK activation and impaired insulin signaling in subcutaneous microvascular endothelial cells in type 2 diabetes: the role of endothelin-1. Diabetes. 2009;58:2238-45.
38. Kubota T, Kubota N, Kumagai H, Yamaguchi S, Kozono H, Takahashi T, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 2011;13:294-307.
39. Zhang J, Ou J, Bashmakov Y, Horton JD, Brown MS, Goldstein JL. Insulin inhibits transcription of IRS-2 gene in rat liver through an insulin response element (IRE) that resembles IREs of other insulin-repressed genes. Proc Natl Acad Sci USA. 2001;98:3756-61.
40. Ide T, Shimano H, Yahagi N, Matsuzaka T, Nakakuki M, Yamamoto T, et al. SREBPs suppress IRS-2-mediated insulin signaling in the liver. Nat Cell Biol. 2004;6:351-7.
41. Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M, et al. A model of the kinetics of insulin in man. J Clin Invest. 1974;53:1481-92.
42. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-23.
43. Chiu JD, Richey JM, Harrison LN, Zuniga E, Kolka CM, Kirkman E, et al. Direct administration of insulin into skeletal muscle reveals that the transport of insulin across the capillary endothelium limits the time course of insulin to activate glucose disposal. Diabetes. 2008;57:828-35.
44. Prager R, Wallace P, Olefsky JM. In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J Clin Invest. 1986;78:472-81.
45. Turk D, Alzaid A, Dinneen S, Nair KS, Rizza R. The effects of non-insulin-dependent diabetes mellitus on the kinetics of onset of insulin action in hepatic and extrahepatic tissues. J Clin Invest. 1995;95:755-62.
46. Sjöstrand M, Gudbjörnsdottir S, Holmäng A, Lönn L, Strindberg L, Lönnroth P. Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes. 2002;51:2742-8.
47. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158-73.
48. King GL, Johnson SM. Receptor-mediated transport of insulin across endothelial cells. Science. 1985;227:1583-6.
49. Dernovsek KD, Bar RS. Processing of cell-bound insulin by capillary and macrovascular endothelial cells in culture. Am J Physiol. 1985;248:E244-51.
50. Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol. 1994;127:1217-32.
51. Steil GM, Ader M, Moore DM, Rebrin K, Bergman RN. Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Invest. 1996;97:1497-503.
52. Hamilton-Wessler M, Ader M, Dea MK, Moore D, Loftager M, Markussen J, et al. Mode of transcapillary transport of insulin and insulin analog NN304in dog hindlimb: evidence for passive diffusion. Diabetes. 2002;51:574-82.
53. Majumdar S, Genders AJ, Inyard AC, Frison V, Barrett EJ. Insulin entry into muscle involves a saturable process in the vascular endothelium. Diabetologia. 2012;55:450-6.
54. Barrett EJ, Wang H, Upchurch CT, Liu Z. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. Am J Physiol Endocrinol Metab. 2011;30:E252-63.
55. Wang H, Liu Z, Li G, Barrett EJ. The vascular endothelial cell mediates insulin transport into skeletal muscle. Am J Physiol Endocrinol Metab. 2006;291:E323-32.
56. Wang H, Wang AX, Barrett EJ. Caveolin-1 is required for vascular endothelial insulin uptake. Am J Physiol Endocrinol Metab. 2011;300:E134-44.
57. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, et al. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem. 2002;277:40091-8.
58. Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes. 1997;46:1381-8.
59. Parks DA, Granger DN. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl. 1986;548:87-99.
60. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97:473-83.
61. Clark MG. Impaired microvascular perfusion: a consequence of vascular dysfunction and a potential cause of insulin resistance in muscle. Am J Physiol Endocrinol Metab. 2008;295:E732-50.
62. Barrett EJ, Eggleston EM, Inyard AC, Wang H, Li G, Chai W, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. Diabetologia. 2009;52:752-64.
63. Vincent MA, Dawson D, Clark AD, Lindner JR, Rattigan S, Clark MG, et al. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes. 2002;51:42-8.
64. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001;104:342-5.
65. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003;285:E123-9.
66. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-5.
67. Andreozzi F, Laratta E, Procopio C, Hribal ML, Sciacqua A, Perticone M, et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol. 2007;27:2372-83.
68. Federici M, Pandolfi A, De Filippis EA, Pellegrini G, Menghini R, Lauro D, et al. G972RIRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation. 2004;109:399-405.
69. Kainoh M, Maruyama I, Nishio S, Nakadate T. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level. Biochem Pharmacol. 1991;41:1135-40.
70. Niwano K, Arai M, Tomaru K, Uchiyama T, Ohyama Y, Kurabayashi M. Transcriptional stimulation of the eNOS gene by the stable prostacyclin analogue beraprost is mediated through cAMP-responsive element in vascular endothelial cells: close link between PGI2 signal and NO pathways. Circ Res. 2003;93:523-30.
71. Lièvre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral Beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprostet Claudication Intermittente (BERCI) Research Group. Circulation. 2000;102:426-31.
72. Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, et al. Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) study group effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-502.
73. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262-9.
74. Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol. 1993;265:L374-81.
75. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209-15.
76. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol. 2010;325:26-35.
77. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012;61:888-96.
78. Clerk LH, Rattigan S, Clark MG. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes. 2002;51:1138-45.
79. Youd JM, Rattigan S, Clark MG. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNF-alpha. Diabetes. 2000;49:1904-9.
80. Zhang L, Wheatley CM, Richards SM, Barrett EJ, Clark MG, Rattigan S. TNF-alpha acutely inhibits vascular effects of physiological but not high insulin or contraction. Am J Physiol Endocrinol Metab. 2003;285:E654-60.
81. Wallis MG, Smith ME, Kolka CM, Zhang L, Richards SM, Rattigan S, et al. Acute glucosamine-induced insulin resistance in muscle in vivo is associated with impaired capillary recruitment. Diabetologia. 2005;48:2131-9.
82. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, Clark MG. Insulin-mediated hemodynamic changes are impaired in muscle of zucker obese rats. Diabetes. 2002;51:3492-8.
83. Jaap AJ, Hammersley MS, Shore AC, Tooke JE. Reduced microvascular hyperaemia in subjects at risk of developing type 2(non-insulin-dependent) diabetes mellitus. Diabetologia. 1994;37:214-6.
84. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2diabetes. Diabetes. 1999;48:1856-62.
85. Serné EH, de Jongh RT, Eringa EC, Ijzerman RG, de Boer MP, Stehouwer CD. Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome. Essays Biochem. 2006;42:163-76.
86. Gudbjörnsdóttir S, Sjöstrand M, Strindberg L, Lönnroth P. Decreased muscle capillary permeability surface area in type 2diabetic subjects. J Clin Endocrinol Metab. 2005;90:1078-82.
87. Daugan A, Grondin P, Ruault C, de Gouville AC LM, Coste H, Linget JM, et al. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J Med Chem. 2003;46:4525-32.
88. Jansson PA, Murdolo G, Sjögren L, Nyström B, Sjöstrand M, Strindberg L, et al. Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes. Diabetologia. 2010;53:2205-8. Technology Technology Technology Technology Technology